Enzymatica AB (publ) (ENZY.ST)
SEK 1.68
(-1.18%)
SEK 1.68
(-1.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -49.72 Million SEK | 27.57% |
| 2022 | -68.65 Million SEK | -51.25% |
| 2021 | -45.39 Million SEK | -243.34% |
| 2020 | -13.22 Million SEK | 67.74% |
| 2019 | -40.97 Million SEK | 3.76% |
| 2018 | -42.57 Million SEK | -35.41% |
| 2017 | -31.44 Million SEK | 30.13% |
| 2016 | -45 Million SEK | -10.23% |
| 2015 | -40.83 Million SEK | -26.05% |
| 2014 | -32.39 Million SEK | -99.86% |
| 2013 | -16.2 Million SEK | -114.16% |
| 2012 | -7.56 Million SEK | -51.75% |
| 2011 | -4.98 Million SEK | 0.0% |
| 2009 | -190.09 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -18.86 Million SEK | -34.15% |
| 2024 Q2 | -13.79 Million SEK | 26.89% |
| 2023 Q3 | -9.23 Million SEK | 19.76% |
| 2023 Q4 | -14.06 Million SEK | -52.24% |
| 2023 FY | -49.72 Million SEK | 27.57% |
| 2023 Q1 | -14.92 Million SEK | 32.74% |
| 2023 Q2 | -11.51 Million SEK | 22.85% |
| 2022 Q3 | -13.06 Million SEK | 14.96% |
| 2022 Q4 | -22.18 Million SEK | -69.79% |
| 2022 FY | -68.65 Million SEK | -51.25% |
| 2022 Q1 | -18.04 Million SEK | -67.74% |
| 2022 Q2 | -15.36 Million SEK | 14.89% |
| 2021 Q2 | -19.66 Million SEK | -121.84% |
| 2021 Q4 | -10.76 Million SEK | -76.22% |
| 2021 FY | -45.39 Million SEK | -243.34% |
| 2021 Q1 | -8.86 Million SEK | -2661.37% |
| 2021 Q3 | -6.1 Million SEK | 68.95% |
| 2020 Q1 | 721 Thousand SEK | 113.51% |
| 2020 Q4 | -321 Thousand SEK | 83.16% |
| 2020 Q3 | -1.9 Million SEK | 83.73% |
| 2020 Q2 | -11.71 Million SEK | -1724.69% |
| 2020 FY | -13.22 Million SEK | 67.74% |
| 2019 FY | -40.97 Million SEK | 3.76% |
| 2019 Q4 | -5.33 Million SEK | 31.12% |
| 2019 Q2 | -15.68 Million SEK | -28.32% |
| 2019 Q1 | -12.21 Million SEK | -66.0% |
| 2019 Q3 | -7.74 Million SEK | 50.61% |
| 2018 Q4 | -7.36 Million SEK | 23.01% |
| 2018 FY | -42.57 Million SEK | -35.41% |
| 2018 Q3 | -9.56 Million SEK | 38.36% |
| 2018 Q2 | -15.51 Million SEK | -52.9% |
| 2018 Q1 | -10.14 Million SEK | -81.06% |
| 2017 FY | -31.44 Million SEK | 30.13% |
| 2017 Q4 | -5.6 Million SEK | -57.3% |
| 2017 Q1 | -11.44 Million SEK | 34.93% |
| 2017 Q2 | -10.83 Million SEK | 5.36% |
| 2017 Q3 | -3.56 Million SEK | 67.12% |
| 2016 Q2 | -12.8 Million SEK | -58.16% |
| 2016 Q3 | -6.5 Million SEK | 49.19% |
| 2016 Q4 | -17.58 Million SEK | -170.27% |
| 2016 Q1 | -8.09 Million SEK | 27.71% |
| 2016 FY | -45 Million SEK | -10.23% |
| 2015 Q3 | -10.13 Million SEK | 3.35% |
| 2015 FY | -40.83 Million SEK | -26.05% |
| 2015 Q4 | -11.2 Million SEK | -10.55% |
| 2015 Q1 | -9 Million SEK | 26.69% |
| 2015 Q2 | -10.48 Million SEK | -16.4% |
| 2014 Q4 | -12.28 Million SEK | -100.34% |
| 2014 Q1 | -6.47 Million SEK | -34.86% |
| 2014 Q3 | -6.13 Million SEK | 18.24% |
| 2014 Q2 | -7.5 Million SEK | -15.9% |
| 2014 FY | -32.39 Million SEK | -99.86% |
| 2013 Q2 | -3.53 Million SEK | -38.85% |
| 2013 Q4 | -4.79 Million SEK | 9.91% |
| 2013 FY | -16.2 Million SEK | -114.16% |
| 2013 Q3 | -5.32 Million SEK | -50.69% |
| 2013 Q1 | -2.54 Million SEK | -17.99% |
| 2012 FY | -7.56 Million SEK | -51.75% |
| 2012 Q3 | -776 Thousand SEK | 79.37% |
| 2012 Q2 | -3.76 Million SEK | -109.13% |
| 2012 Q1 | -1.79 Million SEK | 0.0% |
| 2012 Q4 | -2.15 Million SEK | -178.07% |
| 2011 Q2 | -1.35 Million SEK | 0.0% |
| 2011 FY | -4.98 Million SEK | 0.0% |
| 2011 Q3 | -1.51 Million SEK | -11.89% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q2 | -226.28 Thousand SEK | 0.0% |
| 2010 Q3 | -455.87 Thousand SEK | -101.46% |
| 2009 FY | -190.09 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -263.217% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | -33.796% |
| BioGaia AB (publ) | 365.35 Million SEK | 113.611% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | -11.465% |
| Gabather AB (publ) | -9.43 Million SEK | -426.947% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | -38.967% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | -135.756% |
| Nanexa AB (publ) | -76.39 Million SEK | 34.909% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -222.804% |
| ODI Pharma AB | 355.97 Thousand SEK | 14069.677% |
| Orexo AB (publ) | -128.3 Million SEK | 61.241% |
| Probi AB (publ) | 16.81 Million SEK | 395.666% |
| Swedencare AB (publ) | 58.6 Million SEK | 184.86% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 102.064% |
| Toleranzia AB | -7.45 Million SEK | -566.685% |
| Vivesto AB | -367.03 Million SEK | 86.451% |